Watch hVIVO’s July 2024 Capital Markets Day here
We are a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.
Yamin 'Mo' Khan
CEO at hVIVO
"2024 was a tremendous year for the Group, with the delivery of record revenue and EBITDA margins as well as laying broader foundations for future growth. These record financials were achieved in a year when the Company completed the move to the world's largest commercial human challenge trial unit, developed a number of new challenge models, launched three new service lines, and implemented a number of new software systems. This is all a testament to the hard work and expertise of our world-leading team.
"Our newly launched services executed in our existing infrastructure, benefited our margins and cash generation. I am impressed with how well these new services are performing since their recent launch and this, combined with the expansion of our human challenge offering and strategic M&A (with our first acquisition announced today), has enhanced our ability to deliver revenues of £100 million by 2028."
FY24 Revenue
FY 24 EBITDA Margin
Cash 31 Dec 2024
FY25 Revenue Guidance
Our values
We are a diverse group of individuals working for one team to achieve common goals. Each one of us plays a crucial role in the team's success. We are committed to each other and the team. We learn from our failures together and celebrate our successes together. Diversity and inclusion are at the core of our organisation, and we consider our clients’ success as our own.
We are dedicated to the growth of our colleagues, customers and shareholders. We are committed to our personal growth and the development of our colleagues. We aim to grow our client base and the value of their products. We will repay the trust of our shareholders in achieving greater returns on their investment. We will achieve this by creating a culture of intellectual freedom across the organisation.
We take personal ownership of our actions and always act in ways that builds trust and respect with all our stakeholders. We pride ourselves in maintaining the welfare and the rights of all individuals and ensuring the best outcomes for our participants and patients. We are honest, have strong moral and ethical principles and are reliable and consistent in our delivery.
We are pioneering in our approach, always curious. We use our unique scientific expertise to guide our client’s towards successful outcomes. We embrace new opportunities and rise to new challenges. Our agility allows us to redefine our markets and be highly responsive to our clients’ requirements.
